It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nonalcoholic steatohepatitis (NASH) is triggered by hepatocyte death through activation of caspase 6, as a result of decreased adenosine monophosphate (AMP)-activated protein kinase-alpha (AMPKα) activity. Increased hepatocellular death promotes inflammation which drives hepatic fibrosis. We show that the nuclear-localized mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP1) is upregulated in NASH patients and in NASH diet fed male mice. The focus of this work is to investigate whether and how MKP1 is involved in the development of NASH. Under NASH conditions increased oxidative stress, induces MKP1 expression leading to nuclear p38 MAPK dephosphorylation and decreases liver kinase B1 (LKB1) phosphorylation at a site required to promote LKB1 nuclear exit. Hepatic deletion of MKP1 in NASH diet fed male mice releases nuclear LKB1 into the cytoplasm to activate AMPKα and prevents hepatocellular death, inflammation and NASH. Hence, nuclear-localized MKP1-p38 MAPK-LKB1 signaling is required to suppress AMPKα which triggers hepatocyte death and the development of NASH.
Nonalcoholic steatohepatitis (NASH) is a devastating type of liver disease that is caused by hepatocellular death which triggers liver inflammation and fibrosis. Here, the authors show that MAP kinase phosphatase-1 promotes hepatocellular death thus, driving the development of NASH.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710)
2 University of Alabama, Department of Biological Sciences, Huntsville, USA (GRID:grid.411015.0) (ISNI:0000 0001 0727 7545)
3 Monash University, Monash Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
4 Yale University School of Medicine, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
5 Alfred Hospital, Melbourne, Monash University Department of Surgery, Victoria, Australia (GRID:grid.1623.6) (ISNI:0000 0004 0432 511X)
6 Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710)
7 Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710)
8 Monash University, Monash Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710)
9 Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710)